Statement regarding mailing of interim report

PROTEOME SCIENCES plc PRESS RELEASE Interim Report to 30th June, 2007 8 October 2007. The Directors of Proteome Sciences plc ("Proteome Sciences") announce that copies of the Interim Report for the six months to the 30th June, 2007 were posted to shareholders on Friday 5th October, 2007. Ends Notes to editors: Proteome Sciences plc applies high sensitivity proteomics to identify and characterise differential protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has discovered blood biomarkers principally for stroke, vCJD, BSE, brain damage, solid organ transplant rejection and Alzheimer's disease. The main focus of its research currently addresses neurological, neurodegenerative, oncology and cardiovascular conditions. In addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoSHOP® (Proteome Sciences High Output Proteomics), a toolbox that offers high sensitivity and high throughput gel and gel-free proprietary technologies for the identification and validation of potential biomarkers and drug targets, including specialisation in membrane proteins and protein phosphorylation. The Company has developed a range of specialist reagents to improve the performance and quantitation of protein separation and characterisation with mass spectrometry, bioinformatics, statistics and pattern recognition. These include Sensitizer®, PST®, qPST™ and TMT®. Proteome Sciences has patent allowances in the major global jurisdictions for isobaric tandem mass tags (TMT ®) for the manufacture and use of any type of isobaric mass tags. Commercialisation is actively pursued across the portfolio of the Company's programmes and technologies with licensing deals signed in biomarkers for Stroke and TSEs and for ProteoSHOP®. Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has laboratories at Kings College Hospital, London and Frankfurt Innovations Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its corporate and business development staff, and has collaborative research agreements with leading academic institutes. The Company is listed on the Alternative Investment Market. For further information please visit www.proteomics.com. Proteome Sciences plc Christopher Pearce, Chief Executive Officer James Malthouse, Finance Director Email: christopher.pearce@proteomics.com Email: james.malthouse@proteomics.com Tel: +44 (0)1932 865065 Public Relations IKON Associates Coast Communications Adrian Shaw Matt Baldwin Tel: +44 (0)1483 535102 Tel:+44 (0)1233 503200 Mobile:+44 (0)797 9900733 Mobile:+44 (0)7930 439739 Email: adrian@ikonassociates.com Email: matt@coastcommunications.com Nominated Adviser Landsbanki Securities (UK) Limited Thilo Hoffman - Tel: +44 (0)20 7426 9000